Literature DB >> 7724145

Intrauterine therapy for homozygous alpha-thalassemia.

S Carr1, L Rubin, D Dixon, J Star, J Dailey.   

Abstract

BACKGROUND: Alpha-thalassemia is one of the most common genetic disorders in the world and is becoming more common in the United States with the increase in immigration of susceptible populations. This disease has been stated previously to be incompatible with extrauterine life. CASE: A Filipino woman with a prior loss due to hemoglobin Bart's underwent prenatal diagnosis that confirmed recurrence in the index pregnancy. Intravascular intrauterine exchange transfusions maintained appropriate fetal growth. A cesarean delivery yielded a 2190-g male infant with minor malformations. The postnatal course was characterized by mild respiratory insufficiency. Postnatal chronic transfusion therapy is underway pending consideration for bone marrow transplantation.
CONCLUSION: Antenatal diagnosis and therapy of homozygous alpha-thalassemia can prevent the prenatal consequences of hydrops and fetal death. New technologies such as stem cell transplantation may help to avert both prenatal and postnatal consequences.

Entities:  

Mesh:

Year:  1995        PMID: 7724145     DOI: 10.1016/0029-7844(94)00334-a

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

Review 1.  An international registry of survivors with Hb Bart's hydrops fetalis syndrome.

Authors:  Duantida Songdej; Christian Babbs; Douglas R Higgs
Journal:  Blood       Date:  2017-01-05       Impact factor: 22.113

Review 2.  Clinical manifestations of α-thalassemia.

Authors:  Elliott P Vichinsky
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

3.  A Case of Nonimmune Hydrops Fetalis Caused by Homozygous α-Thalassemia.

Authors:  Melek Akar; Dilek Dilli; Uğur Dilmen
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

Review 4.  In utero hematopoietic cell transplantation for hemoglobinopathies.

Authors:  S Christopher Derderian; Cerine Jeanty; Mark C Walters; Elliott Vichinsky; Tippi C MacKenzie
Journal:  Front Pharmacol       Date:  2015-01-12       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.